Talita Stessuk, PhD, BMN Platform Lead at Crown Bioscience details that by bridging the gap between in vitro studies & in vivo physiology, these models hold the promise of revolutionizing our understanding of the bone marrow microenvironment. hubs.la/Q03BJy_b0

Listen to our CrownCast episode with Enrico Pesenti, Executive Director of Client Engagement, in which he unpacks the complex world of tumor resistance – and the scientific strategies being used to outmaneuver it. hubs.la/Q03BVFT10 #CrownCast

Biorepositories are pivotal in the fast-evolving landscape of biomedical research, serving as essential resources for advancements in oncology. Discover how they underpin translational research: hubs.la/Q03BVF-w0

In this AACR 2025 Poster, we’re showcasing how paired PDX and PDXO models from breast and gastric cancers provide a powerful platform to study efficacy, resistance, and next-gen strategies for DS8201 (Enhertu). Download the poster to find out more: hubs.la/Q03CjSpj0

Biospecimen integrity is essential for generating accurate and reliable results that are reproducible and translatable. Our latest blog post highlights the five quality factors that research teams should be aware of: hubs.la/Q03CwQyY0

If you missed our recent BMN and AML webinar, you can still catch up on all the insights! Watch the recording here: hubs.la/Q03CLXG10

Working with a local CRO offers you a strategic advantage. With Crown Bioscience we remove the location and time zone hurdles so you can make faster, actionable, and more predictive decisions. Learn more about how we can elevate your projects in the USA. hubs.la/Q03CTPTB0

Breast cancer is not one disease; it’s many. The many subtypes of breast cancer create real challenges for drug development – especially in advanced and metastatic stages. Watch the full webinar: hubs.la/Q03D3sql0

Immune checkpoint inhibitors have reshaped oncology, but emerging IO therapies demand models that go further. Join our free webinar, led by Director of Scientific Operations Kiel Peck, PhD. Register now to see our insights in action: hubs.la/Q03DkpNY0

Looking for expert support across the entire drug discovery pipeline? Our DMPK team provides highly customizable, end-to-end solutions across in vitro ADME, in vivo pharmacokinetics, and bioanalysis. Explore our capabilities: hubs.la/Q03DlkrG0

Fast-track your drug development with SynAI – a cutting-edge platform designed to predict drug synergies for cancer therapies using AI. Register for SynAI and gain free access to our AI-driven predictions. Unlock the future of cancer treatment today: hubs.la/Q03DwtD-0

In this CrownCast episode, Professor Thomas Hartung, Chair of Evidence-Based Toxicology at Johns Hopkins Bloomberg School of Public Health discusses how organoids & AI-powered tools are paving the way for more ethical, predictive & human-relevant research.hubs.la/Q03DZh670

Translational oncology research relies on clinically relevant models that can predict how therapies will perform in patients. By delivering greater biological relevance, patient-derived organoid and xenograft models offer a clearer path. Learn more: hubs.la/Q03FrF980

Preclinical drug screening for blood cancers faces a challenge: standard ex vivo models miss the real bone marrow environment. At AACR 2025, we shared a 3D BMN model enabling AML & MM survival, scalable drug screening & more predictive insights. hubs.la/Q03FFs3k0

We’re proud to support some of the world’s most innovative life sciences teams. Together we can realize a world where every patient gets the right treatment, at the right time. Discover more: hubs.la/Q03FRQsw0 #1CX

Step into the future of blood cancer research! Discover how @CrownBioscience’s 3D bone marrow niche model is transforming hemato-oncology. Hear from Dr. Talita Stessuk on how this model could reshape hemato-oncology drug discovery. 👉 Read more: eu1.hubs.ly/H0mFV4C0

In this blog post, we explore how advanced preclinical models offer research teams the tools they need to navigate the challenge of ADC toxicity successfully, and fulfill the promise of this transformative therapy. Read now: hubs.la/Q03G8qH20

Join us at #CICON25 from September 10-12, 2025 in The Netherlands. View our 2 new scientific posters, featuring some of our latest research in the dynamic field of cancer immunotherapy. Meet our colleagues at the event to discuss your research needs. hubs.la/Q03GbLLv0

Get ready for BIOCHINA Global Forum 2025 in Seoul! Whether you’re navigating precision therapeutic development, tackling ADC toxicity challenges, or seeking patient-derived models to de-risk your pipeline, this is your chance to connect with experts. hubs.la/Q03GjRdz0

On Labor Day we thank all our incredible colleagues, partners, and clients. Your dedication is invaluable. Together we can realize a world where every patient gets the right treatment, at the right time.